Anthranilic Acid and Cognitive Impairment
Author Information
Author(s): Gregory Oxenkrug, José Marco-Contelles
Primary Institution: Tufts University School of Medicine
Hypothesis
The anthranilic acid-induced activation of GPR109A inhibits cPLA2, which may prevent cognitive impairment.
Conclusion
The review suggests that anthranilic acid may serve as a new target for treating cognitive impairment in schizophrenia, dementia, and aging.
Supporting Evidence
- The review discusses the impact of anthranilic acid on myelin integrity and cognitive impairment.
- Clinical studies suggest that higher intake of niacin is associated with a slower rate of cognitive decline.
- Anthranilic acid levels were found to be higher in individuals with schizophrenia compared to healthy subjects.
Takeaway
This study looks at how a substance called anthranilic acid might help improve thinking and memory problems in people with certain brain diseases.
Methodology
The review synthesizes recent literature and clinical data regarding the role of anthranilic acid in cognitive impairment.
Limitations
Data on anthranilic acid in neurodegenerative disorders are scarce, and the proposed cascade needs further exploration.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website